Application of astragaloside in preventing and treating type 2 diabetic nephropathy

A technology of type 2 diabetes and astragaloside IV, which is applied in the field of application of astragaloside IV in the preparation of drugs for the prevention and treatment of type 2 diabetic nephropathy, which can solve the problems of no research reports and achieve reduction of urinary NAG and improvement of pathological damage , the effect of reducing the excretion rate of urinary albumin

Inactive Publication Date: 2017-01-11
SHENZHEN TRADITIONAL CHINESE MEDICINE HOSPITAL
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

China CN 1569884A invention patent discloses a preparation method of astragaloside IV and its application in the preparation of drugs for the prevention and treatment of diabetic nephropathy. A rat model of type 1 diabetic nephropathy was constructed by intraperit...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of astragaloside in preventing and treating type 2 diabetic nephropathy
  • Application of astragaloside in preventing and treating type 2 diabetic nephropathy
  • Application of astragaloside in preventing and treating type 2 diabetic nephropathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0022] Embodiments of the present invention will be specifically described below in conjunction with the accompanying drawings.

[0023] Early DN mainly manifested as glomerular hyperfiltration and microalbuminuria, and its pathological changes were mainly glomerular and tubular basement membrane thickening and mesangial expansion. The pathogenesis of DN is still unclear, and treatment methods are scarce. Akt and its related signaling pathways (mTOR, NFκB and Erk1 / 2) play an important role in cell growth and proliferation, and the dysregulation of Akt signaling pathway also plays an important role in human cancer, diabetes, cardiovascular and nervous system diseases. Recent studies have shown that Akt overactivation is closely related to the progression of DN, and statins, troglitazone, rapamycin, or sirolimus can protect the kidneys of DN by inhibiting the overactivation of Akt and its related signaling pathways. Astragaloside IV is the main active ingredient of Astragalus...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to novel application of astragaloside, in particular to application of astragaloside in preventing and treating type 2 diabetic nephropathy, and provides a study on the protective effect and acting mechanism of astragaloside for type 2 diabetic nephropathy. The results indicate that the astragaloside is capable of reducing urinary albumin excretion rate in type 2 diabetic db/db mouse, improving glomerulus and renal tubule pathological injury, and reducing excretion of urine NAG, NGAL and TGF-Beta1. The astragaloside is also capable of inhibiting activation of Akt/mTOR, NFkB and Erk1/2 signal channels, with no significant hepatotoxicity present. In total, the astragaloside can protect type 2 diabetic nephropathy, and its acting mechanism is associated with the inhibition of Akt and its related signal channels.

Description

technical field [0001] The present invention relates to the new application of astragaloside IV, more specifically, the application of astragaloside IV in the preparation of drugs for preventing and treating type 2 diabetic nephropathy. Background technique [0002] Diabetic nephropathy (diabetic nephropathy, DN) is an important complication of diabetes, and has gradually become the main pathogenic factor of chronic kidney disease (chronic kidney disease, CKD). The dysfunction of Akt and its related signaling pathways (mTOR, NFκB and Erk1 / 2) plays an important role in the progression of DN. [0003] Astragaloside IV (AS-IV) is an effective monomer compound extracted from the traditional Chinese medicine Astragali, which can enhance the body's immunity and improve the body's disease resistance. China CN 1569884A invention patent discloses a preparation method of astragaloside IV and its application in the preparation of drugs for the prevention and treatment of diabetic neph...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61P3/10A61P13/12
CPCA61K31/7048
Inventor 李顺民易铁钢孙惠力韩鹏勋邵牧民王文静宋高峰余学问戈娜王太芬
Owner SHENZHEN TRADITIONAL CHINESE MEDICINE HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap